RUXOLITINIB AS TREATMENT FOR CENTRAL NERVOUS SYSTEM ATYPICAL MANIFESTATION OF GRAFT-VERSUS-HOST DISEASE (SIE 2026) - Oct 6, 2026 - Abstract #DP113; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "These two cas- es highlight the complexity of managing CNS-GVHD, from diagnosis to treatment. Ruxolitinib resulted effective leading to a rapid and durable clinical response, normalization of EEG and amelioration of MRI features."
Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Alzheimer's Disease • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Cognitive Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Movement Disorders
|
|
G. Facchin1; A. Geromin1; L. Ml. Battista1; G. Pizzamiglio2; Mc De Colle2; L. Tosoni1; G. Tomadini1; R. Plos1; M. Moratti1; R. Fanin1; F. Patriarca1
|